UPDATE: Stifel Nicolaus Cuts PT to $17 on InterMune Following Guidance

Stifel Nicolaus maintained InterMune (NASDAQ: ITMN ) with a Buy rating and lowered the price target from $19.00 to $17.00. Stifel Nicolaus commented, "Although European regulatory/reimbursement headwinds will likely prevail near-term, we continue to believe management's FY13 sales guidance looks readily achievable and we believe the model could potentially hit